INM News and Press, InMed Pharmaceuticals Inc. From 07/20/23

InMed Pharmaceuticals (NASDAQ: INM) , a leader in the pharmaceutical research, development, manufacturing and commercialization of rare cannabinoids and cannabinoid analogs, today provided a commercial and manufacturing update on its subsidiary BayMedica LLC, a leading supplier of bioidentical ra...

$2.3M revenues (unaudited) in Q4 2023, representing 123% increase quarter over quarter ("QoQ") Optimized and scaled up manufacturing processes over the last 12 months to meet increasing demand Third consecutive quarter with significant revenue growth Vancouver, British Columbia--(Newsfile C...

2023-06-22 13:21:19 ET Gainers: TRxADE HEALTH ( MEDS ) +56% . ShiftPixy ( PIXY ) +45% . Root ( ROOT ) +36% . VCI Global Limited ( VCIG ) +34% . Barfresh Food Group ( BRFH ) +27% . Oncolytics Biotech ( ONCY ) +23% . ...

2023-06-22 10:02:12 ET Gainers: TRxADE HEALTH ( MEDS ) +39% . Talaris Therapeutics ( TALS ) +25% . IGM Biosciences ( IGMS ) +11% . Predictive Oncology ( POAI ) +4% . Zymeworks ( ZYME ) +3% . Losers: Innovative Eyewear...

2023-06-22 08:29:19 ET AlloVir ALVR -23% on pricing $75M of stock offering. Advanced Health Intelligence ( AHI ) -22% . InMed Pharmaceuticals ( INM ) -19% announces results from a phase 2 clinical trial in epidermolysis bullosa . Innovative Eyewear ...

An exploratory clinical evaluation of the Phase 2 clinical trial data showed a positive indication of enhanced anti-itch activity for INM-755 cannabinol (" CBN ") cream versus the control cream alone. The results for non-wound itch were not statistically significant in favor of INM-755 CBN cre...

InMed Pharmaceuticals (NASDAQ: INM) , a leader in the pharmaceutical research, development, manufacturing and commercialization of rare cannabinoids, today announced that results from a neurodegenerative disease study were presented in a scientific poster at the Canadian Neuroscience Meeting in...

Vancouver, British Columbia--(Newsfile Corp. - June 1, 2023) - InMed Pharmaceuticals Inc. ( NASDAQ: INM ) (" InMed " or the " Company "), a leader in the pharmaceutical research, development, manufacturing and commercialization of rare cannabinoids and cannabinoid analogs, today announced that re...

InMed Pharmaceuticals (NASDAQ: INM) , a leader in the pharmaceutical research, development, manufacturing and commercialization of rare cannabinoids and cannabinoid analogs, will be represented at two upcoming investor events. The company announced that members of its executive team will be parti...

Vancouver, British Columbia--(Newsfile Corp. - May 24, 2023) - InMed Pharmaceuticals Inc. ( NASQDAQ: INM ) (" InMed " or the " Company "), a leader in the pharmaceutical research, development, manufacturing and commercialization of rare cannabinoids and cannabinoid analogs, today announce that th...